These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 25014730

  • 1. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
    Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P.
    Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
    [Abstract] [Full Text] [Related]

  • 2. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.
    Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Learoyd DL, Capper D, von Deimling A, Clifton-Bligh RJ, Gill AJ.
    Endocr Relat Cancer; 2012 Dec; 19(6):779-84. PubMed ID: 22997209
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P.
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [Abstract] [Full Text] [Related]

  • 4. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M.
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [Abstract] [Full Text] [Related]

  • 5. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
    Estrella JS, Tetzlaff MT, Bassett RL, Patel KP, Williams MD, Curry JL, Rashid A, Hamilton SR, Broaddus RR.
    Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
    [Abstract] [Full Text] [Related]

  • 6. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X.
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP.
    Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
    [Abstract] [Full Text] [Related]

  • 8. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
    Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP.
    Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
    Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P.
    Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
    Paja Fano M, Ugalde Olano A, Fuertes Thomas E, Oleaga Alday A.
    Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
    [Abstract] [Full Text] [Related]

  • 11. VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients.
    Rashid FA, Tabassum S, Khan MS, Ansari HR, Asif M, Sheikh AK, Sameer Aga S.
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
    Zhang X, Wang L, Wang J, Zhao H, Wu J, Liu S, Zhang L, Li Y, Xing X.
    Exp Mol Pathol; 2018 Aug; 105(1):153-159. PubMed ID: 30009773
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma.
    Kim JK, Seong CY, Bae IE, Yi JW, Yu HW, Kim SJ, Won JK, Chai YJ, Choi JY, Lee KE.
    Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S, Cicciarella Modica DD, Turrini L, Nigri G, Romanelli F, Valabrega S, Giovanella L, Onetti Muda A, Trimboli P.
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [Abstract] [Full Text] [Related]

  • 15. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.
    Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, Deng FM, Patel KN.
    Surgery; 2013 Dec; 154(6):1199-204; discussion 1204-5. PubMed ID: 23931769
    [Abstract] [Full Text] [Related]

  • 16. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
    Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, Lee JH, Lee KH, Park JT.
    Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer.
    Abd Elmageed ZY, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F, Moroz K, Boulares AH, Friedlander P, Miccoli P, Kandil E.
    Surgery; 2017 Apr; 161(4):1122-1128. PubMed ID: 27919446
    [Abstract] [Full Text] [Related]

  • 18. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D, Qi W, Zhang P, Zhang Y, Liu Y, Guan H, Wang L.
    Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, Liang Z.
    Int J Clin Exp Pathol; 2015 Feb; 8(11):15072-8. PubMed ID: 26823846
    [Abstract] [Full Text] [Related]

  • 20. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.
    Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.